Anti–Human Immunodeficiency Virus Drugs Are Ineffective againstPneumocystis cariniiIn Vitro and In Vivo
Author(s) -
Peter D. Walzer,
Alan Ashbaugh,
Margaret S. Collins,
Melanie T. Cushion
Publication year - 2001
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1086/323991
Subject(s) - pneumocystis carinii , saquinavir , in vivo , indinavir , virology , in vitro , pneumonia , biology , immunology , virus , pharmacology , medicine , viral disease , human immunodeficiency virus (hiv) , sida , viral load , biochemistry , microbiology and biotechnology , antiretroviral therapy , pneumocystis jirovecii
Human immunodeficiency virus (HIV) protease inhibitors (PIs) recently have been reported to be active against Pneumocystis carinii in cell culture. Twelve anti-HIV drugs were analyzed for their effects against rat P. carinii by an ATP cytotoxicity assay. Indinavir and saquinavir exhibited slight anti-P. carinii activity at concentrations above those that can be clinically achieved in serum; other PIs and nucleoside and nonnucleoside reverse-transcriptase inhibitors were inactive against the organism. Anti-HIV drugs, alone or in combination, did not materially reduce the organism count in the treatment of P. carinii pneumonia in immunosuppressed mice. Thus, anti-HIV drugs have little or no activity against P. carinii in these in vitro and in vivo systems. Caution should be used when interpreting reports of the susceptibility of P. carinii to anti-HIV drugs on the basis of in vitro testing only.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom